Drug developer Peplin Ltd says it plans to raise about $40 million to fund ongoing clinical development of its proposed fast-action skin cancer gel. Peplin said on Wednesday the money raised will be used to support the ongoing development of its PEP005 Topical compound - a potential treatment for actinic (solar) keratosis, a common skin condition that can develop into skin cancer.
